tezepelumab治疗重度变应性哮喘的临床疗效观察。

IF 2.1 4区 医学 Q3 ALLERGY
Allergologia et immunopathologia Pub Date : 2025-09-16 eCollection Date: 2025-01-01 DOI:10.15586/aei.v53i5.1448
Juan Carlos Miralles-López, Yulia Petryk Petryk, Juan José Cortés Collado, Francisco-Javier Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Sheila Cabrejos-Perotti, José Valverde-Molina, Virginia Pérez-Fernández, Re-Asgramur Group
{"title":"tezepelumab治疗重度变应性哮喘的临床疗效观察。","authors":"Juan Carlos Miralles-López, Yulia Petryk Petryk, Juan José Cortés Collado, Francisco-Javier Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Sheila Cabrejos-Perotti, José Valverde-Molina, Virginia Pérez-Fernández, Re-Asgramur Group","doi":"10.15586/aei.v53i5.1448","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers.</p><p><strong>Methods: </strong>This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed.</p><p><strong>Results: </strong>We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV<sub>1</sub>. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction.</p><p><strong>Conclusions: </strong>Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 5","pages":"193-196"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice.\",\"authors\":\"Juan Carlos Miralles-López, Yulia Petryk Petryk, Juan José Cortés Collado, Francisco-Javier Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Sheila Cabrejos-Perotti, José Valverde-Molina, Virginia Pérez-Fernández, Re-Asgramur Group\",\"doi\":\"10.15586/aei.v53i5.1448\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers.</p><p><strong>Methods: </strong>This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed.</p><p><strong>Results: </strong>We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV<sub>1</sub>. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction.</p><p><strong>Conclusions: </strong>Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.</p>\",\"PeriodicalId\":7536,\"journal\":{\"name\":\"Allergologia et immunopathologia\",\"volume\":\"53 5\",\"pages\":\"193-196\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologia et immunopathologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15586/aei.v53i5.1448\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i5.1448","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

Tezepelumab是一种人单克隆免疫球蛋白G2λ抗体,靶向细胞因子胸腺基质淋巴生成素(TSLP)。在临床试验中,tezepelumab已被证明可以降低高水平和低水平T2炎症生物标志物患者的年化哮喘加重率。方法:这是一项在常规临床实践条件下进行的RE-ASGRAMUR(穆尔西亚地区严重哮喘登记)的前瞻性、多中心研究。我们分析了加重、肺功能(支气管扩张剂前FEV1)、哮喘控制(ACT)和生活质量(mini AQLQ)的变化。此外,还分析了T2生物标志物,包括血液嗜酸性粒细胞和呼出一氧化氮(FeNO)。结果:我们报告了38例接受tezepelumab治疗的严重过敏性哮喘患者。这些患者中有一半以上以前对其他生物疗法反应不足。治疗后,恶化的年化率从基线平均2.2显著下降到0.28,减少了86.8%。哮喘控制测试(ACT)得分平均提高5.2分,而迷你哮喘生活质量问卷(miniAQLQ)得分平均提高1分。肺功能也明显改善,FEV1平均增加170 mL。此外,2型炎症生物标志物,包括血液嗜酸性粒细胞计数和呼出一氧化氮分数(FeNO),显示显着降低。结论:Tezepelumab是一种治疗严重过敏性哮喘的有效药物,可改善急性发作、疾病控制、生活质量和肺功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice.

Introduction: Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers.

Methods: This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed.

Results: We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV1. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction.

Conclusions: Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
131
审稿时长
6-12 weeks
期刊介绍: Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信